In two separate cohorts, e-ILD automated biomarkers applied to baseline HRCT scans predict FVC decline and survival in IPF patients, outperforming change in FVC. WRVS is an imaging biomarker with a clearly defined MCID which incorporates parenchymal and vascular anatomic compartments and is therefore highly prognostic in the short and long-term assessment of IPF. Exploratory clinical trial endpoints combining automated imaging biomarkers with FVC may improve patient selection and definition of treatment response; this is currently being validated in a prospective IPF clinical trial